golf...My expectations are for a share price of $9...or higher if the Brave study for Alzheimers trends positive...even higher if this small study reaches statistical significance ....I expect positive results, but I also expect it might take a larger study than Brave to achieve s.s. and spur the FDA to approve Vascepa for AZ.
Even so ,I think AZ is so common and so devastating... and Vascepa so safe and relatively inexpensive that the FDA could approve it on an interim basis, pending completion of further studies....It would definitely make for make for an interesting Adcom!
News 
Market Data 
Discover 
AI
